Zoetis (ZTS) announced that the Committee for Veterinary Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending the granting of marketing authorization for Lenivia for the reduction of pain associated with osteoarthritis in dogs. Based on the CVMP’s positive opinion, the European Commission is expected to issue a decision during the fourth quarter of 2025, and Zoetis anticipates making Lenivia commercially available in the European Union in 2026. If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor, recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of science and research, with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced increased mobility and decreased pain after one injection.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis Declares Q4 2025 Dividend of $0.50
- Zoetis receives conditional approval for Dectomax-CA1 injectable
- FDA conditionally approves Zoetis’ Dectomax-CA1 in cattle
- Zoetis Positioned for Growth with Innovative Veterinary Pharmaceuticals and Strategic Pipeline Advancements
- Zoetis announces positive opinion from CVMP for Portela